Karnik N D, Bhatt A D, Trivedi T H, Dadkar V N, Kapadia N M, Vaidya A B, Khokhani R C
LTM Medical College and Hospital, Sion, Mumbai.
J Assoc Physicians India. 1996 Jul;44(7):480-2.
In 102 cases of severe hypertension (DBP > or = 115 mm Hg), with or without acute complications, efficacy and safety of SL Nifedipine 10 mg (NIF), SL Captopril 25 mg (CAP), IV Metoprolol 15 mg (MET) and SL NIF + IV MET were studied in an inpatient trial. Maximum mean percent reduction in SBP was 13.3, 9.7, 15.7 and 19.9 and in DBP was 21.2, 13.9, 12.5 and 20.4 with NIF, CAP, MET and NIF + MET respectively. A safe DBP of < or = 110 mm Hg (Kaplan) was achieved in 90, 61, 72.2 and 95.2 percent of patients. A statistically significant fall in DBP was observed at 5 minutes with all regimens except CAP which was at 15 minutes. Mild side effects observed were palpitations and flushing (NIF n = 4), taste disturbances (CAP n = 3), heaviness of head (CAP n = 1) and giddiness (MET n = 2, NIF + MET n = 2). The trial data suggest that hypertensive crisis can be managed, without intensive care facility, with all four regimens; this implies significant cost containment.
在102例重度高血压患者（舒张压≥115mmHg）中，无论有无急性并发症，在一项住院试验中研究了口服硝苯地平10mg（NIF）、口服卡托普利25mg（CAP）、静脉注射美托洛尔15mg（MET）以及口服硝苯地平+静脉注射美托洛尔的疗效和安全性。硝苯地平、卡托普利、美托洛尔以及硝苯地平+美托洛尔治疗后收缩压最大平均降低百分比分别为13.3、9.7、15.7和19.9，舒张压分别为21.2、13.9、12.5和20.4。分别有90%、61%、72.2%和95.2%的患者实现了安全舒张压≤110mmHg（卡普兰标准）。除卡托普利在15分钟时观察到舒张压有统计学意义的下降外，所有治疗方案在5分钟时均观察到舒张压有统计学意义的下降。观察到的轻度副作用有心悸和面部潮红（硝苯地平组n = ）、味觉障碍（卡托普利组n = 3）、头部沉重感（卡托普利组n = ）和头晕（美托洛尔组n = 2，硝苯地平+美托洛尔组n = 2）。试验数据表明，在没有重症监护设施的情况下，所有这四种治疗方案均可用于治疗高血压危象；这意味着可显著控制成本。 （注：原文中“NIF n = 4”等表述似乎不完整，翻译时保留了原文形式）
